Dual therapy for metastatic melanoma results in longer overall survival
by Bruce Sylvester: Patients with metastatic melanoma treated with dual sargramostim/ipilimumab rather than ipilimumab alone have achieved longer overall survival and lower toxicity, but no difference in progression-free… read more.